Huoxue Quscar granules combined with erbium-doped fiber laser therapeutic instrument in the treatment Clinical application of atrophic scars in acne
Abstract
Objective: To compare the clinical efficacy and safety of Huoxue-Quscar granules combined with erbium-doped fiber laser therapeutic instrument and Huoxue-Quscar granules alone in the treatment of atrophic acne scars. Methods: A total of 350 patients with atrophic acne scars treated in our hospital were randomly divided into an experimental group and a control group. The patients in the experimental group were treated with Huoxue-Quscar granules combined with erbium-doped fiber laser therapeutic instrument, and the patients in the control group were treated with Huoxue-Quscar granules. The effective rate and incidence of adverse reactions were compared between the two groups. Results: The effective rate of the trial group was 97.14%, which was significantly higher than 92.00% of the control group (P < 0.05). The incidence of adverse events in the experimental group (0.57%) was lower than that in the control group (4.00%) (P < 0.05).Conclusions: Huoxue-Quscar granules combined with erbium-doped fiber laser therapeutic instrument has good efficacy and safety in the treatment of atrophic acne scars.
References
[1] Mingzi Tu Ye, Jun Zhang, et al. Treatment progress and prospect of facial acne depressed scar [J]. Jiangxi Medicine, 2012,57 (11) :
2025-2027.
[2] State Administration of Traditional Chinese Medicine. Diagnostic efficacy criteria of TCM syndrome [M]. Nanjing: Nanjing University Press, 1994:2 79-280.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.